CPMV (Mosaic ImmunoEngineering) 3-Year Share Buyback Ratio : 0.00% (As of Mar. 2025)

View and export this data going back to . Start your Free Trial

What is Mosaic ImmunoEngineering 3-Year Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Mosaic ImmunoEngineering's current 3-Year Share Buyback Ratio was 0.00%.

The historical rank and industry rank for Mosaic ImmunoEngineering's 3-Year Share Buyback Ratio or its related term are showing as below:

During the past 13 years, Mosaic ImmunoEngineering's highest 3-Year Share Buyback Ratio was 0.50%. The lowest was -108.20%. And the median was -13.80%.

CPMV's 3-Year Share Buyback Ratio is not ranked ^*
in the Biotechnology industry.
Industry Median: -9.7
* Ranked among companies with meaningful 3-Year Share Buyback Ratio only.

Competitive Comparison of Mosaic ImmunoEngineering's 3-Year Share Buyback Ratio

For the Biotechnology subindustry, Mosaic ImmunoEngineering's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mosaic ImmunoEngineering's 3-Year Share Buyback Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mosaic ImmunoEngineering's 3-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Mosaic ImmunoEngineering's 3-Year Share Buyback Ratio falls into.

Save Embed

;

Save Embed

;

Mosaic ImmunoEngineering 3-Year Share Buyback Ratio Calculation

This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Mosaic ImmunoEngineering (OTCPK:CPMV) 3-Year Share Buyback Ratio Explanation

A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Mosaic ImmunoEngineering 3-Year Share Buyback Ratio Related Terms

Thank you for viewing the detailed overview of Mosaic ImmunoEngineering's 3-Year Share Buyback Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Mosaic ImmunoEngineering Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mosaic ImmunoEngineering Inc (OTCPK:CPMV) » Definitions » 3-Year Share Buyback Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

9114 Adams Avenue, Suite 202, Huntington Beach, CA, USA, 92646

Website

https://www.mosaicie.com

Mosaic ImmunoEngineering Inc is a development-stage biotechnology company focused on bridging immunology and engineering to develop novel immunotherapies to treat and prevent cancer and infectious diseases. It has a single operating segment for the purposes of assessing performance and making operating decisions.

Executives

Robert Baffi	director	C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Case Western Reserve University	10 percent owner	10900 EUCLID AVENUE, CLEVELAND OH 44106
Steven W King	director, officer: President and CEO
Paul J Lytle	director, officer: EVP, Chief Financial Officer
Robert L Garnick	director	C/O PATRIOT SCIENTIFIC, 2038 CORTE DEL NOGAL, SUITE 141, CARLSBAD CA 92011
Nicole Franziska Steinmetz	director, officer: Chief Scientific Officer	871 WILBUR AVENUE, SAN DIEGO CA 92019
Dharmesh Mistry	director	315 PEMBROKE COURT, SAN RAMON CA 94582
Carlton M Johnson	director
Donald E Schrock	director	C/O INTEGRATED DEVICE TECHNOLOGY, INC., 6024 SILVER CREEK VALLEY ROAD, SAN JOSE CA 95138
Paul R Bibeau	officer: VP, Business Development	MICROSEMI CORP, 2381 MORSE AVE, IRVINE CA 92614
Frederick C Goerner	officer: Chief Executive Officer	MICROSEMI CORPORATION, ONE ENTERPRISE, ALISO VIEJO CA 92656
Clifford L Flowers	officer: Chief Financial Officer	C/O BAKBONE SOFTWARE, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Harry L Tredennick	director	6183 PASEO DEL NORTE #180, CARLSBAD CA 92011
Thomas J Sweeney	officer: CFO
Helmut Jr Falk	director